Patents Assigned to Millennium Pharmaceuticals, Inc., Delaware corporation
-
Publication number: 20040265303Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: April 16, 2004Publication date: December 30, 2004Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Gregory J. LaRosa, Walter Newman
-
Publication number: 20040235085Abstract: Disclosed are genes found in Streptococcus pneumoniae that are essential for survival for a wide range of bacteria. These genes are termed “S-ylqF,” “S-yqeG,” “S-yybQ,” “S-yerL,” and “S-ysxC.” These genes and the polypeptides that they encode, as well as homologs and orthologs thereof can be used to identify antibacterial agents for treating a broad spectrum of bacterial infections.Type: ApplicationFiled: July 2, 2004Publication date: November 25, 2004Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Christian Fritz, Philip Youngman, Luz-Maria Guzman
-
Publication number: 20040203060Abstract: Increased expression of MDA-9 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of MDA-9, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of MDA-9.Type: ApplicationFiled: May 10, 2004Publication date: October 14, 2004Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: Mark Williamson
-
Publication number: 20040101527Abstract: The invention is based on the discovery that molecules (e.g. a monoclonal antibody or a portion thereof) which bind specifically with the CD18 subunit of a CD18-containing leukocyte cell-surface antigens (e.g. a cell-surface antigen such as Mac-1 which contains both CD18 and a form of CD11) can be used to inhibit, prevent, and alleviate vascular stenotic and restenotic lesions and symptoms and disorders associated with such lesions.Type: ApplicationFiled: November 17, 2003Publication date: May 27, 2004Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: Christopher J. Horvath
-
Publication number: 20030228643Abstract: Disclosed are genes found in Streptococcus pneumoniae that are essential for survival for a wide range of bacteria. These genes are termed “S-ylqF,” “S-yqeG,” “S-yybQ,” “S-yerL,” and “S-ysxC.” These genes and the polypeptides that they encode, as well as homologs and orthologs thereof can be used to identify antibacterial agents for treating a broad spectrum of bacterial infections.Type: ApplicationFiled: April 25, 2003Publication date: December 11, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Christian Fritz, Philip Youngman, Luz-Maria Guzman
-
Publication number: 20030170841Abstract: Novel NBS-1 or PYRIN-1 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated NBS-1 or PYRIN-1 proteins, the invention further provides NBS-1 or PYRIN-1 fusion proteins, antigenic peptides and anti-NBS-1 or anti-PYRIN-1 antibodies. The invention also provides NBS-1 or PYRIN-1 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a NBS-1 or PYRIN-1 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: April 26, 2002Publication date: September 11, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: John Bertin
-
Publication number: 20030170784Abstract: The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to the Mycobacterium tuberculosis hypothetical protein Rv0712, and isolated nucleic acid molecules, designated TANGO 243 nucleic acid molecules, which encode proteins with homology to human PLAP (phospholipase A2-activating protein).Type: ApplicationFiled: March 26, 2002Publication date: September 11, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: Christopher C. Fraser
-
Publication number: 20030166224Abstract: The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.Type: ApplicationFiled: June 7, 2002Publication date: September 4, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Rachel A. Meyers, Nadine Weich
-
Publication number: 20030158398Abstract: The present invention relates of the mammalian HKNG1 gene, a gene associated with bipolar affective disorder (BAD) in humans. The invention relates, in particular, to methods for the diagnostic evaluation, genetic testing and prognosis of HKNG1 neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder.Type: ApplicationFiled: June 4, 2002Publication date: August 21, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Hong Chen, Nelson B. Freimer
-
Publication number: 20030138865Abstract: The invention is based in part on the discovery of a number of genes (HRPCa 2, HPRCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, and HRPCa 19) which are androgen-inducible in androgen-dependent prostate cancer (e.g., LNCaP cells) cells and constitutively expressed in androgen-independent prostate cancer cells (e.g., LN3 LNCaP cells). Because androgen is required for growth and survival of androgen-dependent prostate cancer cells, HRPCa 2, HPRCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, and HRPCa 19 are therapeutic targets. An agent which decreases the expression or activity of HRPCa 2, HPRCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15, or HRPCa 19 may slow or arrest the growth of prostate cancer cells or may kill prostate cancer cells.Type: ApplicationFiled: December 30, 2002Publication date: July 24, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Kyle J. MacBeth, Andrew W. Shyjan
-
Publication number: 20030119740Abstract: The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumor progression in cells involved in human tumors such as melanomas, breast, gastrointestinal, lung, and bone tumors, various types of skin cancers, and other neoplastic conditions such as leukemias and lymphomas. Genes are identified that are differentially expressed in benign (e.g., non-malignant) tumor cells relative to malignant tumor cells exhibiting a high metastatic potential. Genes are also identified via the ability of their gene products to interact with gene products involved in the progression to, and/or aggressiveness of, neoplastic tumor disease states. The genes and gene products identified can be used diagnostically or for therapeutic intervention.Type: ApplicationFiled: October 28, 2002Publication date: June 26, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: Andrew W. Shyjan
-
Publication number: 20030120055Abstract: Novel CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, CARD-5, and CARD-6 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, CARD-5, and CARD-6 proteins, and the invention further provides CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, CARD-5, and CARD-6 fusion proteins, antigenic peptides and anti-CARD-3, anti-CARD-4L and anti-CARD-4S, anti-CARD-4Y, anti-CARD-4Z, anti-CARD-5, and anti-CARD-6 antibodies. The invention also provides CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, CARD-5, and CARD-6 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, CARD-5, and CARD-6 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: November 15, 2002Publication date: June 26, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: John Bertin
-
Publication number: 20030113865Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins.Type: ApplicationFiled: September 25, 2002Publication date: June 19, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: Samantha J. Busfield
-
Publication number: 20030096267Abstract: Disclosed are two genes, termed “yphC” and “yqjK,” found in Streptococcus pneumoniae, which are essential for survival for a wide range of bacteria. These genes and the essential polypeptides that they encode, as well as homologs and orthologs thereof, can be used to identify antibacterial agents for treating a broad spectrum of bacterial infections.Type: ApplicationFiled: July 5, 2002Publication date: May 22, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Christian Fritz, Philip Youngman, Luz-Maria Guzman
-
Publication number: 20030092024Abstract: Disclosed are 23 genes, termed “GEP” genes, found in Streptococcus pneumonia, which are located within operons that are essential for survival. Also disclosed is a related essential gene found in Bacillus subtilis. These genes and the polypeptides that they encode, as well as homologs thereof, can be used to identify antibacterial agents for treating bacterial infections such as streptococcal pneumonia.Type: ApplicationFiled: May 22, 2002Publication date: May 15, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Philip Youngman, Christian Fritz, Christopher Murphy, Luz-Maria Guzman
-
Publication number: 20030082738Abstract: The invention provides isolated nucleic acids molecules, designated 1983, 52881, 2398, 45449, 50289, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 1983, 52881, 2398, 45449, 50289, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 1983, 52881, 2398, 45449, 50289, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 1983, 52881, 2398, 45449, 50289, or 52872 proteins, fusion proteins, antigenic peptides and anti-1983, 52881, 2398, 45449, 50289, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 29, 2002Publication date: May 1, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Maria Alexandra Glucksmann, Katherine M. Galvin, Inmaculada Silos-Santiago
-
Publication number: 20030059892Abstract: Novel TANGO-93 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TANGO-93 proteins, the invention further provides isolated TANGO-93 fusion proteins, antigenic peptides and anti-TANGO-93 antibodies. The invention also provides TANGO-93 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TANGO-93 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: October 9, 2002Publication date: March 27, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: Yang Pan
-
Publication number: 20030003544Abstract: The invention provides isolated nucleic acids molecules, designated 44576 nucleic acid molecules, which encode novel fibroblast growth factor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 44576 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 44576 gene has been introduced or disrupted. The invention still further provides isolated 44576 proteins, fusion proteins, antigenic peptides and anti-44576 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: April 30, 2002Publication date: January 2, 2003Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Nadine S. Weich, Maria Alexandra Glucksmann
-
Publication number: 20020197693Abstract: Novel CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, and murine CARD-4L polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, and murine CARD-4L proteins, and the invention further provides CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, and murine CARD-4L fusion proteins, antigenic peptides and anti-CARD-3, anti-CARD-4L and anti-CARD-4S, anti-CARD-4Y, anti-CARD-4Z, and anti-murine CARD-4L antibodies. The invention also provides CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, and murine CARD-4L nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-3, CARD-4L, CARD-4S, CARD-4Y, CARD-4Z, and murine CARD-4L gene has been introduced or disrupted. The invention further provides CARD-3 and CARD-4 target proteins that bind to CARD-3 or CARD-4 and allelic variants of human CARD-4.Type: ApplicationFiled: April 9, 2002Publication date: December 26, 2002Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventor: John Bertin
-
Publication number: 20020182676Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: ApplicationFiled: February 19, 2002Publication date: December 5, 2002Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White